MX2015003810A - Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina. - Google Patents

Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.

Info

Publication number
MX2015003810A
MX2015003810A MX2015003810A MX2015003810A MX2015003810A MX 2015003810 A MX2015003810 A MX 2015003810A MX 2015003810 A MX2015003810 A MX 2015003810A MX 2015003810 A MX2015003810 A MX 2015003810A MX 2015003810 A MX2015003810 A MX 2015003810A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition according
metadoxine
prednisone
metadoxin
Prior art date
Application number
MX2015003810A
Other languages
English (en)
Spanish (es)
Inventor
Frederick Van Gulik
Yamsani Madhusudan Roa
Shankar Bodapunti Prabha
Original Assignee
Eurodrug Lab B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Lab B V filed Critical Eurodrug Lab B V
Publication of MX2015003810A publication Critical patent/MX2015003810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2015003810A 2012-09-26 2013-01-22 Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina. MX2015003810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2012004028 2012-09-26
PCT/EP2013/000183 WO2014048511A1 (fr) 2012-09-26 2013-01-22 Métadoxine pour utilisation dans le traitement de maladies du foie, et formulations à libération prolongée de métadoxine

Publications (1)

Publication Number Publication Date
MX2015003810A true MX2015003810A (es) 2015-07-17

Family

ID=47018954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003810A MX2015003810A (es) 2012-09-26 2013-01-22 Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.

Country Status (6)

Country Link
KR (1) KR20150063040A (fr)
BR (1) BR112015006642B1 (fr)
MX (1) MX2015003810A (fr)
PE (1) PE20151323A1 (fr)
PH (2) PH12015500353A1 (fr)
WO (1) WO2014048511A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976970A (zh) * 2014-06-06 2014-08-13 程奉平 美他多辛缓释片的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301108C (zh) * 2004-10-15 2007-02-21 山东齐都药业有限公司 美他多辛分散片及其制备方法
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
MX2008010233A (es) * 2008-03-10 2009-11-10 Eurodrug Lab B V Composicion de liberacion modificada, que comprende doxofilina.
IT1393338B1 (it) * 2009-03-06 2012-04-20 Baldacci Lab Spa Uso terapeutico della metadoxina come inibitore della fibrosi epatica.
CN102481291B (zh) * 2009-06-25 2015-10-21 阿尔考布拉有限公司 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法
WO2011061743A1 (fr) * 2009-11-18 2011-05-26 Alcobra Ltd. Métadoxine et dérivés destinés à une utilisation dans le traitement d'une inflammation et de troubles associés à l'immunité

Also Published As

Publication number Publication date
KR20150063040A (ko) 2015-06-08
BR112015006642A2 (pt) 2017-07-04
PE20151323A1 (es) 2015-10-10
PH12016501553B1 (en) 2017-09-11
BR112015006642B1 (pt) 2022-08-02
PH12015500353A1 (en) 2015-04-20
PH12016501553A1 (en) 2017-09-11
WO2014048511A1 (fr) 2014-04-03

Similar Documents

Publication Publication Date Title
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
ES2378255T3 (es) Titulación de tapentadol
JP5612473B2 (ja) 難聴を処置又は予防するための１−アミノ−アルキルシクロヘキサン誘導体
KR20100129264A (ko) 타펜타돌 조성물
KR101710792B1 (ko) 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
BR112012028035B1 (pt) formulação de liberação imediata
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
US20230338367A1 (en) Treatment of prurigo nodularis
US8367107B2 (en) Solid pharmaceutical preparation
US20160151332A1 (en) 4-Methylpyrazole Formulations
US20110251239A1 (en) Combination therapy for the treatment of dementia
US20230277629A1 (en) Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders
US20180008592A1 (en) Treatment of uremic pruritus
WO2020014342A1 (fr) Traitement des symptômes prurigineux de la maladie du foie
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
KR101380813B1 (ko) 2형 당뇨병 치료용 병용 의약
US20200179292A1 (en) Therapeutic composition and methods
RU2008108216A (ru) Фармацевтические дозированные формы и составы, содержащие лекозотан
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
CN114401724B (zh) 一种降糖药物组合物